Related Experiment Video
Updated: Jul 19, 2025
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Beneficial Effects of Angiotensin II Receptor Blockers on Mortality in Patients with COVID-19: A Retrospective Study
1Division of Cardiology, Department of Internal Medicine, Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095# Jiefang Ave., Wuhan, 430030, China.
Insights
Angiotensin II receptor blockers (ARBs) significantly reduced mortality in COVID-19 patients with cardiovascular diseases. This large study provides evidence supporting ARB use for better outcomes in this vulnerable population.
Area of Science:
- Cardiology
- Infectious Diseases
- Pharmacology
Background:
- COVID-19 poses a significant global health challenge, particularly for individuals with cardiovascular diseases (CVDs).
- While angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are recommended for these patients, evidence supporting their efficacy in COVID-19 is limited.
- This study addresses the need for robust data on ARB use in COVID-19 patients with CVDs.
Purpose of the Study:
- To investigate the association between angiotensin II receptor blocker (ARB) administration and clinical outcomes in patients diagnosed with both COVID-19 and cardiovascular diseases (CVDs).
- To evaluate the efficacy of ARBs in reducing mortality among this high-risk patient group.
Main Methods:
- A multicenter retrospective study involving 11,231 patients with confirmed COVID-19 and CVDs from 138 hospitals.
- Comparison of clinical characteristics and outcomes between patients receiving ARBs and those who did not.
- Risk factor analysis for in-hospital death using univariate and multivariate Cox regression and Kaplan-Meier curves.
Main Results:
- Multivariate Cox regression revealed that ARB use was associated with significantly lower all-cause mortality (adjusted HR, 0.53; P < 0.001).
- Propensity score-matched analysis confirmed this association, showing a reduced risk of all-cause mortality with ARB use (adjusted HR, 0.62; P = 0.02).
- Subgroup analyses indicated that ARB use was linked to lower mortality in patients with heart failure, diabetes, hypercholesterolemia, and severe COVID-19.
Conclusions:
- Angiotensin II receptor blocker (ARB) administration demonstrates a significant association with a reduced risk of all-cause mortality in patients co-infected with COVID-19 and cardiovascular diseases.
- These findings support the beneficial role of ARBs in managing COVID-19 patients with underlying cardiovascular conditions.
Background:
The COVID-19 pandemic has become a serious global public health problem. Although the use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor type 1 blockers (ARBs) has been recommended in patients with COVID-19 and cardiovascular diseases (CVDs), according to the results of some small-sample retrospective analyses, there remains a lack of sufficient evidence to validate their efficacy. This multicenter retrospective study investigated whether ACEI/ARB administration was beneficial in patients with COVID-19 and CVDs.
Methods:
A total of 11,231 patients with confirmed COVID-19 and CVDs, from 138 hospitals in Hubei Province, were included in this multicenter retrospective study. We compared the clinical characteristics and outcomes between the ARB and non-ARB groups and analyzed the risk factors for in-hospital death using univariate and multivariate Cox regression analyses and Kaplan-Meier curves.
Results:
In the multivariate Cox regression model, after adjusting for age, gender, comorbidities, and in-hospital medications, ARB use was associated with lower all-cause mortality (adjusted HR, 0.53; 95% CI, 0.38-0.73; P < 0.001). After propensity score-matched analysis, the adjusted HR for the use of ARB associated with all-cause mortality was 0.62 (95% CI, 0.40-0.88; P = 0.02). Further subgroup analyses found that the adjusted HRs for the use of ARB associated with all-cause mortality were 0.52 (95% CI, 0.30-0.89; P = 0.016), 0.37 (95% CI, 0.21-0.64; P < 0.001), 0.42 (95% CI, 0.28-0.64; P < 0.001), and 0.55 (95% CI, 0.37-0.84; P = 0.005) in patients with heart failure, diabetes, and hypercholesterolemia, and severe COVID-19, respectively.
Conclusions:
ARB administration was significantly associated with a lower risk of all-cause mortality in patients with COVID-19 and CVDs.
Trial Registration:
ClinicalTrials.gov NCT05615792. https://www.
Clinicaltrials:
gov/ct2/show/NCT05615792.
More Related Videos
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
08:21A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
01:25Antihypertensive Drugs: Direct Renin Inhibitors
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
01:22Heart Failure Drugs: β-Blockers
01:30Heart Failure V: Medical Management